News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

April 6, 2023

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

March 29, 2023

Affimed Reports 2022 Financial Results and Operational Progress

March 23, 2023

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

March 16, 2023

Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research

March 14, 2023

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

February 22, 2023

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

February 8, 2023

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

January 9, 2023

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/ Refractory Acute Myeloid Leukemia

December 22, 2022

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

December 12, 2022

Events

All

Scientific

Investors

26Sep

NK2023

September 26 - 29, 2023 (Oslo, Norway)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

Affimed Reports 2022 Financial Results and Operational Progress

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/ Refractory Acute Myeloid Leukemia

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

Events

NK2023